Unum Therapeutics Inc. (UMRX) Misses Q1 EPS by 6c

Unum Therapeutics Inc. (NASDAQ: UMRX) reported Q1 EPS of ($0.39), $0.06 worse than the analyst estimate of ($0.33). Revenue for the quarter came in at $3.05 million versus the consensus estimate of $3.11 million.

“We remain on track to deliver on key milestones across our pipeline of hematologic and solid tumor cancer programs,” said Chuck Wilson, President and CEO of Unum. “The dose escalation phases of our non-Hodgkin lymphoma, multiple myeloma, and HER2+ advanced cancer trials based on our Antibody-Coupled T cell Receptor (ACTR) platform are proceeding as planned, positioning us to report data and drive decisions on next steps. Simultaneously, we continue to advance and expand our preclinical pipeline of Bolt-On Chimeric Receptor (BOXR) programs, aiming to address the unmet need in solid tumor cancers by engineering improved T cell functionality.”

For earnings history and earnings-related data on Unum Therapeutics Inc. (UMRX) click here.

You May Also Be Interested In

• Citi agrees to acquire rewards platform Kard Financial
• 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
• Innovaro (INV) Misses Q2 EPS by 9c